Patientenpräferenzen in der Dermatologie

Zusammenfassung

Es wird immer häufiger gefordert, individuelle Bedürfnisse und Präferenzen der Patienten verstärkt in die therapeutische Entscheidungsfindung einzubeziehen. Hauterkrankungen, besonders wenn sie chronisch verlaufen, beeinflussen das physische, psychische, berufliche und soziale Wohlbefinden der Patienten. Dabei ist nicht nur die Erkrankung selbst, sondern auch die gewählte Therapie ausschlaggebend. Entstehen zwischen den Präferenzen der Patienten und der vom Arzt gewählten Therapie Diskordanzen, kann dies zu einer Unzufriedenheit mit der Therapie führen und eine geminderte Compliance/Adhärenz verursachen. Es wurde gezeigt, dass dermatologische Patienten definierte Präferenzen aufweisen und eine Adressierung dieser Präferenzen zu einer höheren Therapiezufriedenheit führt. Übergeordnetes Ziel ist es, im Zuge des „shared decision makings“ eine größere Patientenzufriedenheit, eine verbesserte Compliance/Adhärenz und somit ein verbessertes Therapieergebnis und eine optimierte Versorgung von Patienten zu erzielen.

Abstract

There is a growing advocacy to incorporate patients’ individual needs and preferences in treatment decision making. Skin diseases, especially when chronic, can strongly affect the physical, emotional, professional and social well-being of patients. Thereby the determining factor is not only the disease, but also its management. Discordance between a recommended treatment and patients’ preferences can cause dissatisfaction with as well as less compliance/adherence to treatments. It was shown that dermatological patients have defined preferences and an incorporation of these preferences improves treatment satisfaction. The superior goal within the process of “shared decision makings” is to increase treatment satisfaction, facilitate compliance/adherence and thereby improve outcome and optimize medical care.

• Literatur

• 1 Pflugfelder A, Kochs C, Blum A et al. S3-guideline “diagnosis, therapy and follow-up of melanoma” -- short version. J Dtsch Dermatol Ges 2013; 11: 563-602
• 2 Nast A, Boehncke WH, Mrowietz U et al. S3-Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges 2013; 10 (Suppl. 02) 1-95
• 3 Carroll CL, Feldman SR, Camacho FT et al. Better medication adherence results in greater improvement in severity of psoriasis. Br J Dermatol 2004; 151: 895-897
• 4 Herberger K, Heyer AK, Blome C et al. Development and Use of Guideline-Derived Quality Indicators for Community Lymphoedema. J Eur Acad Dermatol Venerol 2013; 27: 227-234
• 5 Augustin M, Rustenbach SJ, Debus S et al. Quality of Care in Chronic Leg Ulcer in the Community: Introduction of Quality Indicators and a Scoring System. Dermatology 2011; 222: 321-329
• 6 Brennan PF, Strombom I. Improving health care by understanding patient preferences: the role of computer technology. J Am Med Inform Assoc 1998; 5: 257-262
• 7 Koehler AM, Maibach HI. Electronic monitoring in medication adherence measurement. Implications for dermatology. Am J Clin Dermatol 2001; 2: 7-12
• 8 Barbosa CD, Balp MM, Kulich K et al. A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence. Patient preference and adherence 2012; 6: 39-48
• 9 Augustin M, Kruger K, Radtke MA et al. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 2008; 216: 366-372
• 10 Dowlatshahi EA, Wakkee M, Arends LR et al. The Prevalence and Odds of Depressive Symptoms and Clinical Depression in Psoriasis Patients: A Systematic Review and Meta-Analysis. J Invest Dermatol 2008; 134: 1542-1551
• 11 Blome C, Simianer S, Purwins S et al. Time needed for treatment is the major predictor of quality of life in psoriasis. Dermatology 2010; 221: 154-159
• 12 Dubertret L, Mrowietz U, Ranki A et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 2006; 155: 729-736
• 13 Muhlbacher AC. Der Analytic Hierarchy Process (AHP): Eine Methode zur Entscheidungsunterstützung im Gesundheitswesen. PharmacoEconomics 2014;
• 14 Zschocke I, Hammelmann U, Augustin M. Therapeutischer Nutzen in der dermatologischen Behandlung – Bewertung von Therapieerfolg aus Arzt- und Patientenperspektive bei Psoriasis und atopischer Dermatitis. Hautarzt 2005; 56: 839-846
• 15 Schaarschmidt ML, Schmieder A, Umar N et al. Patient preferences for psoriasis treatments: process characteristics can outweigh outcome attributes. Arch Dermatol 2011; 147: 1285-1294
• 16 Augustin M, Holland B, Dartsch D et al. Adherence in the treatment of psoriasis: a systematic review. Dermatology 2011; 222: 363-374
• 17 van Cranenburgh OD, de Korte J, Sprangers MA et al. Satisfaction with treatment among patients with psoriasis: a web-based survey study. Br J Dermatol 2013; 169: 398-405
• 18 Ross CK, Steward CA, Sinacore JM. The importance of patient preferences in the measurement of health care satisfaction. Med Care 1993; 31: 1138-1149
• 19 Helm R, Steiner M. Präferenzmessung: Methodengestützte Entwicklung zielgruppenspeziefischer Produktinnovationen. Stuttgart: Kohlhammer; 2008
• 20 Delfino Jr M, Holt EW, Taylor CR et al. Willingness-to-pay stated preferences for 8 health-related quality-of-life domains in psoriasis: a pilot study. J Am Acad Dermatol 2008; 59: 439-447
• 21 Krammer R, Heinzerling L. Therapy preferences in melanoma treatment -- willingness to pay and preference of quality versus length of life of patients, physicians and healthy controls. PLoS One 2014; 9: e111237
• 22 Schmitt J, Meurer M, Klon M et al. Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based study. Br J Dermatol 2008; 158: 351-359
• 23 Zug KA, Littenberg B, Baughman RD et al. Assessing the preferences of patients with psoriasis. A quantitative, utility approach. Arch Dermatol 1995; 131: 561-568
• 24 Lundberg L, Johannesson M, Silverdahl M et al. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol 1999; 141: 1067-1075
• 25 Opmeer BC, Heydendael VM, deBorgie CA et al. Patients with moderate-to-severe plaque psoriasis preferred oral therapies to phototherapies: a preference assessment based on clinical scenarios with trade-off questions. J Clin Epidemiol 2007; 60: 696-703
• 26 Augustin M, Radtke MA, Zschocke I et al. The patient benefit index: a novel approach in patient-defined outcomes measurement for skin diseases. Arch Dermatol Res 2009; 301: 561-571
• 27 Kellett N, West F, Finlay AY. Conjoint analysis: a novel, rigorous tool for determining patient preferences for topical antibiotic treatment for acne. A randomised controlled trial. Br J Dermatol 2006; 154: 524-532
• 28 Tinelli M, Ozolins M, Bath-Hextall F et al. What determines patient preferences for treating low risk basal cell carcinoma when comparing surgery vs imiquimod? A discrete choice experiment survey from the SINS trial. BMC Dermatol 2012; 12: 19
• 29 Torbica A, Fattore G, Ayala F. Eliciting preferences to inform patient-centred policies: the case of psoriasis. PharmacoEconomics 2014; 32: 209-223
• 30 Muhlbacher AC, Juhnke C. Patient preferences versus physicians’ judgement: does it make a difference in healthcare decision making?. Appl Health Econ Health Policy 2013; 11: 163-180
• 31 Eastman WJ, Malahias S, Delconte J et al. Assessing attributes of topical vehicles for the treatment of acne, atopic dermatitis, and plaque psoriasis. Cutis 2014; 94: 46-53
• 32 Umar N, Yamamoto S, Loerbroks A et al. Elicitation and use of patients’ preferences in the treatment of psoriasis: a systematic review. Acta Derm Venereol 2012; 92: 341-346
• 33 Kromer C, Schaarschmidt ML, Schmieder A. Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment. PLoS One 2015; 10: e0129120
• 34 Schaarschmidt ML, Umar N, Schmieder A et al. Patient preferences for psoriasis treatments: impact of treatment experience. J Eur Acad Dermatol Venereol 2013; 27: 187-198
• 35 Schmieder A, Schaarschmidt ML, Umar N. Comorbidities significantly impact patients' preferences for psoriasis treatments. J Am Acad Dermatol 2012; 67: 363-372
• 36 Keating NL, Guadagnoli E, Landrum MB et al. Treatment decision making in early-stage breast cancer: should surgeons match patients’ desired level of involvement?. J Clin Oncol 2002; 20: 1473-1479
• 37 Gattellari M, Butow PN, Tattersall MH. Sharing decisions in cancer care. Soc Sci Med 2001; 52: 1865-1878
• 38 Shabason JE, Mao JJ, Frankel ES et al. Shared decision-making and patient control in radiation oncology: implications for patient satisfaction. Cancer 2014; 120: 1863-1870
• 39 Umar N, Schaarschmidt M, Schmieder A et al. Matching physicians’ treatment recommendations to patients’ treatment preferences is associated with improvement in treatment satisfaction. J Eur Acad Dermatol Venereol 2013; 27: 763-770
• 40 Albrecht KJ, Nashan D, Meiss F et al. Shared decision making in dermato-oncology: preference for involvement of melanoma patients. Melanoma Res 2014; 24: 68-74
• 41 Say RE, Thomson R. The importance of patient preferences in treatment decisions – challenges for doctors. Br Med Journal 2003; 327: 542-545